News

Novartis announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia…
Read More...

Biogen Inc. and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and…
Read More...

Iterum Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ORLYNVAH (sulopenem etzadroxil and probenecid) for the…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with…
Read More...

AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier…
Read More...

Astellas Pharma Inc. announced the company's decision to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal…
Read More...

TreeFrog Therapeutics has announced a research collaboration with the University of Pittsburgh focused on the potential of tertiary lymphoid structures (TLS) in immuno-oncology, an…
Read More...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) approved the indication extension for DARZALEX (daratumumab) subcutaneous…
Read More...

Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous…
Read More...

Be Biopharma, Inc. announced key milestones alongside a new round of funding as its lead program, BE-101 for Hemophilia B, enters the clinic, and its second development candidate for…
Read More...

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI…
Read More...

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO  (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF)…
Read More...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise…
Read More...

SELLAS Life Sciences Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to Galinpepimut-S (GPS), an…
Read More...

Firefly Neuroscience, Inc. an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental…
Read More...

Viatris Inc. announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. for sotagliflozin in all markets outside of the United States and Europe.…
Read More...

AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with Radiopharm Ventures…
Read More...

Exelixis, Inc. and Merck, known as MSD outside of the United States and Canada, announced that the companies have entered into a clinical development collaboration to evaluate the…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with unresectable,…
Read More...